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ABSTRACT
Bromocriptine, a D2 dopamine receptor (D2R) agonist, is used clinically as a treatment
for pituitary tumors of a lactotroph origin. Many questions remain unanswered about the
mechanism of this effect. The antiproliferative effect has not been demonstrated in DMS
53 cell line, a Small Cell Lung Cancer (SCLC). In this thesis, we have shown that
treatment with NPA (N-propylnorapomorphine), a dopamine receptor agonist inhibits
ERK phosphorylation and proliferation in DMS 53 cells. NPA treatment causes
significant increases in DUSP-1 (MKP-1), DUSP-4 (MKP-2) and DUSP5 mRNA. NPA
treatment also correlates with increases in DUSP5 (hVHR3) protein visualized using
Western Blot. These three genes were also induced by treatment with exogenous
arachidonic acid (AA). In addition, the NPA mediated increases in these genes was
inhibited by 5,8,11,14-eicosatetraynoic acid (ETYA) an AA analog and inhibitor of
downstream activity, suggesting NPA induction of these three genes is AA dependent.
Ethanol treatment leads to inhibition of the NPA induction of DUSP4 and DUSP5,
suggesting phosphatidic acid (PA) produced from Phospholipase D (PLD) is involved in
this induction.
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CHAPTER 1. INTRODUCTION
DOPAMINE
Distribution of Dopamine Signaling
Dopamine (DA) is a catecholamine derived from Tyrosine in a two step enzymatic
process. The limiting step in this process, catalyzed by L-Dopa Decarboxylase removes
the carboxyl group from L-Dopa (Nolte 2002). DA neurons are found in the olfactory
bulb, the hypothalamus and the in the ventral midbrain. Substantia nigra pars compacta
neurons project through the nigrostriatal pathway to the striatum (London 2002), while
Ventral Tegmental Area neurons project to a variety of locations throughout the central
nervous system (Prakash 2006; Sillitoe 2008). Neurons in the Ventral Tegmental area
project through the mesocortical and mesolimbic pathways to regulate a multitude of
behavioral functions (Sillitoe 2008). DA neurons in the olfactory bulb are involved in
processing sensory information from olfactory receptor neurons (Cave 2009).
Hypothalamic Neurons project to cells through the tuberoinfundibular pathway to the
pituitary (Prakash 2006; Wojcikowski 2009).
Functions
CNS DA signaling regulates mood, cognition, attention, reward, reinforcement of
addiction, and stress, motor control and neuroendocrine control (Bjorklund 2007; Missale
et al 1998; Schulz 2007; Sillitoe 2008; Smidt 2003; Wise 2004). In the periphery, DA
regulates vascular tone, catecholamine release, hormone secretion, renal action and
gastrointestinal motility (Missale 1998). DA indirectly influences changes in the
periphery, by regulating circulating growth hormone and triiodothyronine levels
(Wojcikowski 2009).
Epidemiology/Involvement in Diseases
A number of drugs interact with the DA receptor family, including the antipsychotics and
tricyclic antidepressants. For example, DA antagonists such as Haloperidol are used as
antipsychotic drugs in the treatment of schizophrenia (Kuroki 2008). DA is implicated in
a multitude of other diseases such, ADHD (Kieling 2010), Parkinson’s disease
(Hornykiewicz 2008; Prakash 2006), in addition to reinforcement of addictions to drugs
and alcohol (Ross and Peselow 2009; Sillitoe 2008).

1

Receptors
DA receptors are classic G-Protein coupled receptors with seven transmembrane
domains. Five DA receptors exist, which are encoded by distinct genes, D1-D5. DA
receptors signal to a variety of cellular signaling functions, including activation or
inhibition of adenylyl cyclase (Stoof and Kebabian 1984), activation of potassium
conductance (Sasaki and Sato 1987), the inhibition of votage-gated calcium currents
(Lledo 1992), inositol phosphate production (Mahan 1990), AA metabolism (Kanterman
1991; Piomelli 1991) and stimulation of PLD (Senogles 2000). DA receptors are grouped
into two classes based on the ability to activate (D1R-like) or inhibit (D2R-like) adenylyl
cyclase (Stoof and Kebabian 1984). The various DA receptors also differ in binding
affinities for agonists and antagonists (Table 1.1) (Missale 1998).
D2R Dopamine Receptor Signaling
Activation of D2R DA receptors inhibits adenylyl cyclase (De Camilli 1979; McDonald
1984), voltage gated calcium currents (Lledo 1992) and activates potassium conductance
(Einhorn 1991) and stimulates PLD (Senogles 2000). D2R DA receptors (D2R) exist in
two different isoforms, D2R Long (D2Rl) and D2R short (D2Rs) a result of alternative
mRNA splicing (Dal Toso 1989). To date, all tissues which express D2R DA receptors
express both isoforms, but at different ratios (Mansour 1989; Watson 1990).
D2R DOPAMINE RECEPTOR MEDIATED CHANGES IN
ANTIPROLIFERATION
Pituitary
Prolactin secreting pituitary adenomas have been treated clinically using Bromocriptine,
a D2R agonist for many years (Colao 2002; Melmed 1998; Wass 1979). DA agonists
have also been shown to reduce tumor mass of pituitary adenomas in patients (McGregor
1979). Addition of DA agonists has been shown to inhibit proliferation in anterior
pituitary cells (Pawlikowski 1978) and primary lactotroph cultures (Stepien 1978). The
antiproliferative effects of DA happen in the presence or absence of serum in the culture
medium (Florio 1992; Senogles 1994). In contrast, stimulation of proliferation has been
reported in D2R transfected Chinese hamster ovary (CHO) cells and C6 Glioma cell
lines. In these cases, the proliferative effect was inhibited with pertussis toxin, indicating
the involvement of Gi/o family of G-proteins and is most likely mediated by cAMP.
However, the antiproliferative effect is pertussis toxin insensitive, suggesting another
signaling pathway is involved (Senogles 2000).
The GH4C1 cell line has been widely used to study the antiproliferative effects of DA.
This cell line was cloned from a rat pituitary tumor and secretes prolactin and growth
hormone, mimicking isolated primary lactotrophs in culture (Tashjian 1968). However,
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Table 1.1. Inhibition Constants for Dopamine Receptor Antagonists and Agonists.
Receptor

D1 like
D1R
D5R

D2R

D2R like
D3R

D4R

Antagonists
(+)-Butaclamol
Chlorpromazine
Clozapine
Eticlopride
Haloperidol
Nemonapride
Spiperone

++++
++
++
++
ND
++

+++
++
++
++
ND
+

++++
++++
++
+++++
+++++
+++++
+++++

ND
+++
++
ND
+++
+++++
++++

+++
+++
+++
++++
++++
+++++
+++++

Agonists
Apomorphine
Bromocriptine
Dopamine
7-OH-DOPAT
Quinpirole

+
++
+
+
-

++
++
++
ND
ND

++++
++++
++
+++
+

+++
++++
+++
++++
+++

++++
++
+++
+
+++

Note: +++++, Inhibition constant(K)<0.5nM; ++++, 0.5nM<K<5nM;
+++, 5nM<K<50nM ; ++, 50nM,K<500nM; + ,500nM<K<5 µM -,K>5 µM; ND, not
determined; 7-OH-DPAT,7-hydroxy-dipropylaminoetetralin. Modified with permission.
Missale C, Russle N, Robinson S, Jaber M, Caron M. (1998). Dopamine receptors: from
structure to function. Physiological Reviews. 78(1):189-220.
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GH4C1 cells do not endogenously express D2R (Cronin 1980) and thus are unresponsive
to DA (Malarkey 1977). GH4ZR7 cells (Albert 1990) and GH4-121 cell lines (Senogles
1994) were created by stably transfecting GH4 C1 cells with the cDNA coding for the
D2Rs DA receptor.
Bromocriptine (Florio 1992), DA and NPA (Senogles 1994) treatment of the GH4ZR7
cell line inhibits proliferation, as demonstrated by reduced [3H] thymidine incorporation
and a reduction in cell number.
One group reported that the reduction in growth correlated with an increase in protein
tyrosine phosphatase activity and that the reduction of proliferation was inhibited by
pertussis toxin at concentrations of 180 ng/ml (Florio 1992). Senogles (1994) reported
that at concentrations of 20 ng/ml pertussis toxin had no effect on the D2R mediated
antiproliferation. This author also demonstrated complete ADP-ribosylation of Gi/Go by
this concentration of pertussis toxin. Pertussis toxin insensitivity indicates the
antiproliferative effect does not require the heterotrimeric Gi/Go family of G Proteins
(Fields and Casey 1997). Since the D2R mediated signaling effects on inhibition of
adenylyl cyclase, inhibition of voltage gated calcium channels and activation of voltage
gated calcium channels are in fact inhibited by pertussis toxin this suggests the existence
of other D2R mediated pathways.
Phorbol Ester downregulation of Protein Kinase C (PKC) blocked DA inhibition of
prolactin release in primary lactotrophs (Summers 1985). Thus, PKC was investigated as
a signaling intermediate in the antiproliferation signaling pathway. In GH4ZR7 cells,
down-regulation of PKC by phorbol esters and selective downregulation of PKC epsilon
by Thyrotropin Releasing Hormone abolished D2R inhibition of [3H] thymidine
incorporation (Senogles 1994) and suggested a PKC intermediate.
Typical isoforms of PKC are activated by DAG. Activation of Phospholipase C, (PLC)
which generates DAG and inositol phosphate (IP3) by the hydrolysis of (PIP2), was a
potential source of DAG. However, D2Rs signaling did not stimulate increased inositol
phosphate metabolism in lactotrophs (Vallar 1990) or GH4C1 cells (Senogles 1994).
Another cellular source of DAG is from PA by the action of PLD. PLD activity was
stimulated by D2Rs in GH4-121 cells (Senogles 2000). The activation of PLD was
reported to be dependent on RhoA (Senogles 2003), but independent of PLC activation
(Senogles 2000). Treatment of cells with 0.5% Ethanol resulted in inhibition of D2Rs
mediated antiproliferation in these cells (Senogles 2003), which further implicated the
role of PLD.
Small Cell Lung Cancer (SCLC)
The antiproliferative effect of DA agonists has also been in seen in SCLC, when D2R
agonists inhibited growth of tumor xenografts of SCLC cell lines NCI-H69 and COR
L103 in athymic nude mice (Ishibashi 1994). The antiproliferative effect, in response to a
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DA agonist, was in fact demonstrated through a reduction of [3H] thymidine
incorporation as well as reduced cell number in NCI-H69 cells, a clonal SCLC cell line
(Senogles 2007).
Pituitary cells required transfection of the cDNA encoding the D2R in order to study the
antiproliferative pathway. Questions arise about artifacts existing resulting from D2R
transfection. SCLC cells provide a possible model to study antiproliferation without
transfection. A SCLC cell line NCI-H69 expresses both the D2Rs and D2Rl isoforms as
shown by PCR and real time PCR (Cooper and Sprio 2006; Senogles 2007).
Approximately 20-25% of lung cancers were of the small cell variety in 1994 (Chia
1994). That number has decreased in the past 30 years (Field and Duffy 2008) and now
represents about 13% of newly diagnosed lung cancer cases (Puglisi 2010). Small Cell
Lung Cancer (SCLC) is an aggressive form of cancer with early local and distant
metastases (Puglisi 2010). The prognosis of SCLC cases is poor even with early
diagnosis. SCLC responds initially to chemotherapy and radiation, but becomes resistant.
Due to a high reoccurrence rate and development of drug resistance (ZangemeisterWittke and Stahel 1999), only 20-40% of limited diagnoses and 5% of extensive
diagnoses patients survive greater than two years (Lally 2007; Puglisi 2010). More than
90% of cases involved patients with a history of smoking (Brownson 1992).
POTENTIAL PATHWAYS FOR SIGNALING IN ANTIPROLIFERATION
Lipid Metabolism
Activation of the D2Rs stimulates PLD in stably transfected D2Rs transfected GH4C1
cells, HEK 293 cells (Senogles 2000) and in native NCI-H69 cells (Senogles 2007). PLD
enzymes respond to many different stimuli including cytokines, growth factors
neurotransmitters resulting in abundant amount of cellular processes to include
mitogenesis, oncogenesis and metabolic regulation (Exton 2002). Phospholipase enzymes
catalyze the hydrolysis of ester or phosphodiester linkages of phospholipids (Morris
1997). PLD (Figure 1.1) catalyzes the hydrolysis of Phophatidylcholine (PC) resulting in
the formation of phosphatidic acid (PA) and choline (Exton 2002).
Two form of PLD exist, namely PLD1 and PLD2 (Hammond 1995). PLD1 has a low
basal activity and is regulated by a number of different factors such as many cytokines,
hormones, neurotransmitters (Exton 2002). Protein Kinase C along with members of the
Ras superfamily of low molecular weight GTP binding proteins, particularly ADP
Ribosylation factor (ARF) and RhoA (Hammond 1995; 1997; Kanaho 1996) activatate
PLD1. PLD2 exhibits a high basal activity (Exton 2002), however is regulated by PKC
and ARF (Weernink 2007).
PA signaling is responsible for many of the cellular actions resulting from PLD
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Figure 1.1. Phospholipase Action. Phospholipase D catalyzes the hydrolysis of
phosphatidyl choline to phosphatidic acid and choline. Phospholipase C catalyzes the
hydrolysis of phosphatidyl inositol species to diacylglycerol and inositol phosphate.
PLA2 catalyzes the cleavage of diacylglycerol to monoacylglycerol and AA.
activation. PA can be further metabolized to DAG through phosphatidic
phosphohydrolase (PAP) or to lysophosphatidic acid as catalyzed by phospholipase A2
(PLA2) (Exton 2002). In these cells, PA is involved in many processes to include
membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival
(Weernink 2007). AA (5,8,11,14-eicosatetraenoic acid), a 20 carbon fatty acid is
metabolized through several pathways, including the cycloxygenase (COX) pathway,
lipoxygenase (LOX) pathway and epoxygenase pathway (Irvine 1982; Sigal 1991).
Experimental evidence supports the role of AA in a pathway not associated with classical
Gi/Go stimulated adenylyl cyclase. D2R have been known to generate AA independent
of adenylyl cyclase in anterior pituitary cells (Canonico 1989) and in Chinese hamster
ovary cells (Kanterman 1991; Piomelli 1991). In transfected CHO cells, AA release was
dependent on PKC, calcium (Piomelli 1991) and cytosolic PLA2 (Piomelli and Vial
1995).
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Inhibition of Downstream Signaling from PLD by the Addition of Primary Alcohols
PLD activity is measured by a transphosphatidylation reaction where, in the presence of
primary alcohols, the alcohols substitute for water in the hydrolysis reaction, forming
phosphatidyl alcohol product (Morris 1997). Thus, when ethanol is added to cultured
cells, PLD will form the product, phosphatidylethanol which can be distinguished from
PA on the basis of its migration on a thin layer chromatography plate. The phosphatidyl
alcohol is generated instead of the naturally occurring PA and as a result, addition of
ethanol to cells in culture inhibits downstream PA signaling due to the production of
phosphatidyl ethanol.
Inhibition of ERK Phosphorylation
Unpublished results from our laboratory suggest that agonist-stimulation of D2R
stimulation in in NCI H69 cells, a SCLC cell line, led to a reduction in phosphorylated
ERK (pERK) levels. It was determined by Western blotting with a pERK specific
antibody, that NPA treatment of cells would result in a reduced immunoreactivity. In
addition, lysates from these cells were used in an in vitro kinase reaction and showed that
the ERK kinase activity was also reduced. This data suggests that either the upstream
kinase, MEK was inhibited or that a phosphatase was activated. Our laboratory has
previously demonstrated that MEK activity was not changed by addition of NPA, so we
focused our attention on the possibility of involvement of ERK specific phosphatases.
ERK 1/2 are members of the MAP kinase family. Mitogen-activated protein kinases
(MAPKs) constitute a family of proteins central to many cellular functions, including
proliferation, differentiation, cytoskeletal rearrangement, immune function, stress
responses and apoptosis. The extracellular signal-related kinases (ERKs) were the first
MAPKs elucidated and are comprised of p42 and p44 (ERK 1/2) and ERK 5. The stress
activated protein kinases (SAPKs) are further broken down into the c-Jun N-terminal
kinases (JNKs), consisting of (JNK 1, JNK 2 and JNK 3) and the p38 MAPKs (alpha,
beta, gamma, delta) (Zhou 2004). MAPKs are activated by dual phosphorylation of a TX-Y motif, whereby both phosphorylation events are required to activate kinase activity.
Classic signaling of MAPKs involves a three level cascade where each kinase in the
cascade is activated through phosphorylation by an upstream kinase (Zhou 2004).
Signaling occurs through a variety of receptors such as seven transmembrane receptors
(Caunt 2006) or receptor tyrosine kinases (McCay 2007).
Many questions about the mechanism in which ERKs participate in response to multiple
stimuli remain unanswered. While ERK phosphorylation was originally believed to be
the only determinant required for ERK activation, evidence has shown other factors are
required (Caunt 2006). The strength, duration of the signal, as well as localization, play
significant roles in the differential responses to agonists. Epidermal growth factor (EGF)induced proliferation depends on transient activation of ERK1/2 in the cytosol, whereas
nerve growth factor (NGF)-induced differentiation requires a sustained activation and
translocation to the nucleus (Keyse 2006).
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Varied cellular responses to different stimuli are due to the number of factors which
interact with ERK. A large number of ERK substrates exist, including other kinases,
phosphatases and transcription factors. Some of these factors regulate transcription of
immediate early genes, resulting in quick and dramatic changes in gene expression
(Caunt 2006).
In addition to many different substrates, a wide variety of upstream activators exist. This
effect is compounded as a large number of isoforms exist at all three tiers of the MAPK
cascade. The ability to interact with both upstream regulators and downstream targets is
critical in determining the outcome of MAPK signaling. These interactions depend on
localization, compartmentalization and scaffolding molecules (Caunt 2006).
Much of the research involving ERK involves proliferation and growth factor stimulation
and sustained expression of ERK is necessary for progression from G1 to S phase
(Pouyssegur 2007). In cells lacking growth factor stimulation, ERK is sequestered in the
cytoplasm by MEK (mitogen activated ERK specific kinase), a MAPKK (Fukuda 2000).
Following activation, ERK localizes to the nucleus. Different ERK signal duration and
localization yield different results, however the exact reason for this difference is not
completely understood. Activated ERK accumulates in the nucleus, during mid G1 phase
(Volmat 2001) and initiates transcription of immediate early genes in both mitogenic and
non-mitogenic stimulation (Pouyssegur 2007).
Dual Specificity Phosphatases (DUSPs)
Phosphatase activity acts in opposition of upstream phosphorylation events in the MAPK
cascade. As we had seen reduced pERK in other cell lines in response to DA agonists, we
hypothesize that this change may be the result of increased phosphatase activity. The
MAP Kinase Phosphatases, also known as DUSPs were a potential source of the
increased phosphatase activity as this family of proteins regulates the MAPK family.
DUSPs are a family of phosphatases comprised of a C-terminal catalytic domain with
homology to VH-1 phosphatase of vaccinia virus, a non-catalytic domain, which contains
two regions with homology to cdc25 phosphatase, and a kinase interaction motif (KIM)
(Keyse 2006). As MAPK activation requires dual phosphorylation on both threonine and
tyrosine residues, removal of either phosphate results in reduced MAPK activity.
DUSPs reside in various cellular locations and maintain different specificity for MAPKs
(Keyse 2006). They are divided into three groups, the nuclear inducible, cytosolic ERK
specific and cytosolic nonspecific DUSPs. The nuclear DUSPs include MKP-1
(DUSP1), DUSP2, MKP-2 (DUSP4) and DUSP5. Of this group, DUSP5 is the only one
specific to ERK. The others have activity toward all three MAPKs. The second and third
group consists of cytosolic DUSPs, further divided by the specificity for MAPKs. The
ERK specific DUSPs are DUSP 6 (MKP-3) and DUSPs 7 and 9 (MKP-4), while the
JNK, p38 specific DUSPs are DUSP 8,10 and 16 (Owens and Keyse 2007; Zhou 2004).
See Table 1.2 for specificities.
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Table 1.2. DUSP Family Members.
Gene

MKP

DUSP1
DUSP4
DUSP2
DUSP5
DUSP6
DUSP7
DUSP9

MKP-1
MKP-2
PAC-1
Hvh-3,b23
MKP-3
MKP-X
MKP-4

Subcellular
localization
Nuclear
Nuclear
Nuclear
Nuclear
Cytoplasmic
Cytoplasmic
Cytoplasmic

Substrate preference
JNK,p38, ERK
JNK,p38, ERK
ERK,p38
ERK
ERK
ERK
ERK>p38

Note: DUSPs studied belong to the MAP Kinase Phosphatase family and many have
additional names. Listed are other commonly used names for these phosphatases. In this
thesis DUSP names have been used. DUSPs are either cytoplasmic or nuclear inducible
gene. Modified with permission. Owens DM, Keyse SM. (2007). Differential regulation
of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 26:320313.
HYPOTHETICAL PATHWAY
We hypothesize that the D2R mediated antiproliferative effect are the result of signaling
through PLD. As shown in Figure 1.2 the agonist activation of results in the activation of
PLD. We hypothesize that PA is metabolized to AA by either the action of cPLA2 or the
sequential hydrolysis of PA by PAP and DAG lipase. We hypothesize that AA or a
product of AA metabolism results in an increase of DUSP expression. The increase in
DUSP activity reduces pERK and diminishes proliferation (Figure 1.2). D2R stimulation
of PLD in GH4-121 cells, HEK (Senogles 2000) and SCLC cell lines (Senogles 2007)
has been documented previously.
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Figure 1.2. Hypothetical Pathway. D2R dopamine receptor induction of dual specificity
phosphatases leading to reduced ERK 1/2 phosphorylation.
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CHAPTER 2. MATERIALS AND METHODS
CELL CULTURE
Human, SCLC Lung Cancer cells line, DMS 53 cells, (ATCC CRL-2062) are a tumor
cell line established using cells from a 54 year old caucasian male. These cells are
adherent cells which grow with epithelial-like morphology (Pettingil 1980). The DMS 53
Cell line was maintained Waymouth’s MB 752/1 medium (Gibco) supplemented with
10% FBS (Atlanta Biologicals) and 50 ug/ml Gentimycin. Cell cultures were kept in 5%
CO2 at 37o C.
Passaging of cells and preparation of cells for experiments was performed as follows.
DMS 53 cells were grown to confluency in 2-75 cm2 flasks. Media was aspirated and
cells were washed with 1X PBS. At this point, 1 mL of 0.05% Trypsin/EDTA was added
to each flask and allowed to incubate until cells began to round up. Cells were suspended
in complete media, split 14:1 into 2 – 6 well plates for the experiment, discarding
remaining cells and media. The other flask was split 2:1 into new 75 cm2 flasks.
Following the 24 hour timeframe, experiment specific treatments were added.
NPA TREATMENT AND CYQUANT NF CELLULAR PROLIFERATION
ASSAY
Cyquant NF cellular proliferation assay was carried out as recommended by
manufacturer (Invitrogen). Cells from one 75 cm2 flask were Trypsinized and counted on
a hemacytometer and serial diluted. Dilutions containing total cell numbers of 10000,
5000, 4000, 3000, 2000, 1000, 500, 400, 300, 200, 100 cells/well were created in 100
uL, giving six replicates per dilution. Each dilution was plated to a 96 well plate NPA (1
µM final) in dissolved in 10 µM HCl, final concentration, or 10 µM HCl as a vehicle
control were added giving three replications per condition and allowed to incubate
overnight. Dye binding solution was added and the assay was carried out as
recommended by manufacturer. Plates were excited at 485 nm and detection of
fluorescence was carried out at 530 nm.
REAL TIME PCR
Concept
The probe and primer combination in the LightCycler480 uses Fluorescence Resonance
Energy Transfer technology for specificity, where primers specific for the gene in
question give a large level of specificity. The probes, approximately five nucleotides in
length, add another level of specificity as only in an area of cDNA where both primer and
probe bind will result in fluorescence. A reporter and a quencher fluorophore are present
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on the probe. When intact, the reporter is quenched and no fluorescence occurs. When
polymerase extends from the primer, the probe is removed one nucleotide at a time,
separating the quencher from the reporter fluorophore, thus enabling fluorescence to be
observed (Information from Roche Light Cycler Product Guide).
Treatment and RNA Isolation
Cells grown in 6 well cluster plates were grown to 70-80% and the media was aspirated.
Cells were washed with 1X PBS and 3 mL of complete media was added. Cells were
allowed to grow in this media for 24 hours in order to partially deplete catecholamines
present in the serum. At this time, treatments were added for each individual experiment
and incubated in media at 37o C in 5% CO2. Following the completion of incubation in
experimental conditions, cells were aspirated, washed, lysed and RNA extracted
following the RNA II manufactures protocol (Clontech).
RNA was purified by Sodium Acetate and Ethanol Precipitation. Concentration of the
RNA, A260/280 and A260/230 ratios were determined using the Nanodrop
spectrophotometer. RNA integrity was determined using Agilent Bioanalyzer. RNA
with 8.0 RNA Integrity Number (R.I.N.) or greater were retained, standardized using
total RNA (1200 ng), reverse transcribed to cDNA using Transcriptor First Strand
Synthesis Kit following the manufacturer’s protocol. cDNA was added to Light Cycler
480 probes master (Roche) and Crossing points (CP) were determined using Taqman
protocol on LightCycler 480.
Primer Design
Primers were designed using the Universal Probe Library found at https://www.rocheapplied-science.com/sis/rtpcr/upl/ezhome.html (Roche Diagnostics 1996-2010) (accessed
February 29, 2008). Suggested primer sequences were compared to reported sequences
for all eight DUSPs tested. If any primer had less than two mismatches in sequence, a
separate set of primers was selected and verified. Primers were verified using a real time
PCR standard curve. cDNA were serial diluted 10 fold, to give known relative
concentrations. See Tables 2.1 and 2.2 for primer and probes used.
Calculations
Cycle number is inversely proportional to initial copy number of cDNA. Copy number
must reach a threshold before fluorescence reaches logarithmic and linear phases. Each
cycle doubles the concentration of cDNA, drawing closer to and eventually surpassing
this threshold. The point at which fluorescence changes enter the logarithmic phase is
defined as the crossing point (CP). Determining the exact point is difficult and requires
some interpretation. In this assay, CP values were calculated from highest 2nd derivative
or inflection point of the curve.
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Table 2.1. Left Primer Information.
Gene

Accession #

Amplicon

UPL Catalog
number

Probe
#

Sequence 5' to 3'

Length

DUSP1

NM_004417.2

64

04688643001

65

21

DUSP2

NM_004418.2

91

04688040001

44

DUSP3

NM_004090.2

112

04687639001

30

CGA GGC CAT TGA CTT CAT
AGA
GAC TCC AGG GCT CCT GTC
TA
CGG ATC TAC GTG GGC AAC

DUSP4

NM_001394.5

87

04686900001

17

DUSP5

NM_004419.3

93

04685024001

5

DUSP6

NM_001946.2

112

04688651001

66

DUSP7

NM_001947.2

96

04685130001

14

DUSP9

NM_001395.1

103

04687949001

36

DUSP14

NM_007036.2

81

04686959001

22

TGC ATC CCA GTG GAA GAT
AA
ACA AAT GGA TCC CTG TGG
AA
CGA CTG GAA CGA GAA TAC
GG
CCC ATC TCT GAC CAC TGG
AG
CAC TAC AAG CAG ATC CCC
ATC
GCA CAC TGG ACT CTT GAG
GAA

13

mRNA
position
Begin
End
962
982

20

569

588

18

160

177

20

1120

1139

20

929

948

20

789

808

20

796

815

21

864

884

21

182

202

Table 2.2. Right Primer Information.
Gene

Sequence 5' to 3'

MW

Length

DUSP1

CTG GCA GTG GAC AAA CAC C

5806.8

19

DUSP2

GCA GGT CTG ACG AGT GAC TG

6198.1

20

640

659

DUSP3

TGT TGA CGT GCA TGA AGG A

5907.9

19

253

271

DUSP4

GCA GTC CTT CAC GGC ATC

5435.6

18

1189

1206

DUSP5

CCT TTT CCC TGA CAC AGT CAA

6301.1

21

1001

1021

DUSP6

TTG GAA CTT ACT GAA GCC ACC T

6694.4

22

879

900

DUSP7

CAG GAC ACC ACA CTT GG

6062.0

20

872

891

DUSP9

CGC AGT TCT GGG ACA AGG

5564.7

18

949

966

DUSP14

CGG CAA GAC CAG AGT GTT TT

6157.0

20

243

262

14

mRNA
position
Begin
End
1007
1025

A grouping forms for each dilution of cDNA (Figure 2.1) with the full concentration on
the left and each successive, 10 fold, dilution causes the shifting of the curve to the right
approximately 3.32 cycles (Equation 2.1).
Log2 10=3.32

Equation 2.1

This equation was the basis for the concentration curve. Determining the difference
between the actual changes in molecules per cycle gives the efficiency of the reaction. As
the real time PCR progresses, each cycle doubles the concentration of cDNA. Efficiency
of this curve was measured based on the ability to double with each successive cycle.
Efficient primers which double each cycle would change 3.32 cycles between each ten
fold dilution. A linear concentration curve was generated, where the log of the
concentration was plotted on the x-axis and the corresponding CP value plotted on the yaxis (Figure 1.3). Efficiency can be determined based on the reverse operation of
Equation 2.1 as shown in Equation 2.2 (Bustin 2004).
Efficiency=10 (-1/slope)-1

Equation 2.2

Efficiency of this curve was measured based on the ability to double with each successive
cycle. If the efficiency was below 1.8, alternative primers were selected. Figure 2.2
shows the standard curve for DUSP1.
Change in expression was determined using the ∆∆ CT method, where the slope of the
efficiency curve was assumed to be two. Triplicate CP values were determined and
averaged for the gene of interest and cyclophilin D standard for each cDNA. Delta CT
was determined by subtracting the CP Value of Cyclophilin from that of each gene,
giving every sample (one well from the six well plate) a Delta CT value. Because
concentration doubles each cycle, subtracting CP values is the same as subtracting the
logarithm of the concentration or dividing the concentrations. ∆∆ CT was then
determined by subtracting the CP values determined from vehicle control from those of
determined from cDNA derived from experimental conditions. If ∆∆ CT was negative,
meaning fold change was positive, Equation 2.3 was used to determine fold change
(Bustin 2004).
Fold Change=2(-∆∆ CT)-1

Equation 2.3

In the cases where ∆∆ CT was positive, Equation 2.4 was used to determine mean fold
expression change.
Fold Change=-2 (∆∆ CT)+1

Equation 2.4

Statistics
Determination of ∆∆ CT statistic represents an n value of one. Thus, one cell culture well,
containing the experimental treatment was compared to another well containing the
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Figure 2.1. Real Time PCR Amplification Curves. Figure shows the fluorescence
changes of DUSP1 concentration curve. Successive ten-fold serial dilutions of cDNA
were made. Identical concentrations group together, giving similar Crossing point (CP)
values. CP value is the theoretical point where fluorescence leaves the baseline, but is
determined by the point of highest 2nd derivative. Change in expression is proportional to
the change in CP values.

Figure 2.2. Standard Curve for DUSP1. This is an example of the curves used to
determine efficiency of primers in real time PCR.
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control for an n value of one. One set of RNA and subsequently one cDNA was
generated from each well, thus each number (n) was a separate experiment. In order to
prevent a batch effect, real time PCR was performed over the course of several days.
Each cDNA from treated cells was only compared to those of controls generated on the
same day, however. Hypothesis tests where NPA was compared to vehicle were
performed to obtain fold change data. A value of zero represented the null hypothesis.
An unpaired students t-test was performed comparing fold change over vehicle to the null
hypothesis of zero change. For inhibition experiments (AA, Ethanol and ETYA)
hypothesis testing was carried out using a two-tailed unpaired t-test.
Selection of Cyclophilin D as a Reference Gene
Prior to any real time PCR analysis, cells were treated with appropriate concentration of
drugs of interest. For example 1 µM NPA, 100 µM NPA or Vehicle was used in NPA
experiment. Three individual experiments were performed and RNA was extracted and
reverse transcribed to cDNA. As an effective standard, we sought out a gene of which
expression did not change following application of drugs of interest. Real time PCR was
performed in triplicate for each cDNA using primers for six different human
housekeeping genes including Cyclophilin D, beta actin, beta 2 microglobulin, beta
glucuronidase, TATA box binding protein, transferin receptor. Expression of each gene
was compared to concentration of the drugs of interest and correlation coefficients and R
squared values were calculated for each gene. None of the housekeeping genes analyzed
had greater than 0.15 R squared value. The Cyclophilin D gene at R squared equal to 0.04
was the lowest of any of these genes, indicating that this gene changed very little in
response to drug addition. Thus, cyclophilin D was selected as the reference gene used to
standardize the Real time PCR experiments.
WESTERN BLOT
DMS 53 cells were split into 2 – 6 well plates, plated at a density of 105 cells/well and
grown to 70-80% confluency at which point the media was aspirated, cells were washed
and complete media was added. Drugs of interest were added and cells were lysed.
At the time of lysis, cells were aspirated, washed with PBS. Cells were kept on ice, where
they were lysed using with 600 uL ice cold RIPA buffer (25 mM Tris-HCl pH 7.6, 150
mM NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS), containing protease inhibitor
cocktail (P8340 Sigma, containing AEBSF for serine proteases, Aprotinin for serine
proteases, Bestatin hydrochloride for aminopeptidases, E-64 for cysteine proteases,
Leupeptine hemisulfate salt for serine and cysteine proteases and Pepstatin A for acid
proteases) for 15 min. Following this incubation, lysates were passed several times
through a 21 gauge needle and once again placed on ice for 30 minutes. Lysates were
pelleted via centrifugation at 10000 X G. Supernatents were removed and stored
overnight at -20o C and the pellets were discarded.
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Protein concentrations were determined using the Bradford method (1976) with Bradford
Reagent (BioRad) using Bovine Serum Albumin as the standard. Samples were boiled 5
min and mixed with 2X sample buffer (Laemmli 1970). Routinely a total protein
concentration of 50 ug was loaded and subjected to electrophoresis through a 12% SDSPAGE (Laemmli 1970) gel at 100 V. Proteins were transferred to nitrocellulose
membrane by blotting at 110 V for 1 hr. Membranes were blocked overnight in Blotto A
(5% nonfat dry milk in, 0.01% Tween 20). Membranes were incubated in primary
antibody for 1 hour at ambient temperature, washed 3 X 15 minutes in PBS-T (1 X PBS
+ 0.01% Tween 20). Primary antibody dilution used were Rabbit IgG polyclonal antiDUSP5 (281-295) (sigma # D8819) 1:1000 or anti-pERK at 1:1500 (Abcam #ab65142),
anti-Beta Actin mouse monoclonal IgM (Oncogene Sciences) at 1:1200. The secondary
Ab used were Goat anti rabbit 1:1000) Horseradish Peroxidase (HRP) Conjugate
(Biorad) for DUSP5 and pERK. For actin a secondary HRP conjugate (Oncogene
Sciences #JA1200) was used (1:1500). Membranes were visualized using Enhanced
Chemiluminescence Substrate (Western Lightning).
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CHAPTER 3. RESULTS
D2R DOPAMINE RECEPTOR MEDIATED ANTIPROLIFERATION IN DMS 53
CELLS
Experimental Reasoning
The D2R mediated antiproliferative effects have been well established in D2R transfected
lactotroph cells, HEK cells and native NCI-H69 SCLC cell lines. NPA addition to all of
these cultures consistently results in reductions in [3H] thymidine incorporation and
concomitant reductions in cell numbers. We chose to characterize DMS 53 cells, which
form a monolayer as opposed to NCI-H69 cells, which are suspension cells. We needed
to confirm that D2R stimulation indeed resulted in the antiproliferative pathway in DMS
53 cells. We assessed changes in proliferation following addition of NPA, a D2R agonist,
using the Cyquant Cell Proliferation Assay (Invitrogen).
Results of D2R Mediated Antiproliferation
The proliferation assay confirmed preliminary results that NPA treatment resulted in a
reduction in proliferation and cell number (Figure 3.1). The Cyquant assay measures the
DNA present in cells and is used as a reliable measure of cell number. Results of this
assay revealed a 27% reduction in proliferation (p<0.001) with 1 µM NPA addition
overnight at 10000 cells plated (Figure 3.1). Significant reductions in fluorescence of
36%, 14% and 31% were witnessed when 5000 (p<0.001), 4000 (p<0.05) and 2000
(p<0.05) cells were plated respectively. Mean fluorescence levels decreased in cells
treated with NPA. As shown, the relative fluorescence changed with cell number, which
shows this assay is linear over a large range of cell numbers (500-10,000) used in this
experiment. The reduction in proliferation shown in this assay confirmed results observed
in our laboratory, using other methods such as [3H] thymidine incorporation or counting
of cell number after Trypan blue exclusion staining. Overall, this experiment
demonstrated that the DMS 53 cells, a SCLC cell line, responds to treatment with NPA, a
D2R agonist by decreasing proliferation.
The results seen here demonstrate that NPA a DA agonist leads to reduction in
proliferation in the SCLC cell line, DMS53. The 27% reduction in proliferation was
modest; however it was performed in a relatively short time period of 4 hours. Changes in
proliferation were confirmed with changes in cell count performed with a hemacytometer
(Data not shown). The reduction in proliferation generated in this assay is routinely less
than that observed with [3H] thymidine incorporation (about 50%) in our laboratory
(Senogles unpublished).
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Figure 3.1. NPA Inhibition of Proliferation in DMS 53 Cells. Total cell numbers were
plated as indicated above and treated in the presence (squares) or absence of NPA
(circles) overnight prior to the detection of fluorescence.
Discussion of D2R Mediated Antiproliferation
The Cyquant cell proliferation assay uses a permeant Cyquant GF dye. The fluorescent
dye is enhanced when binding to cellular nucleic acids and incorporates to DNA when
cells are dividing. The changes in cell number correlate well with those seen in [3H]
thymidine incorporation assays (Jones 2001). As a result, changes in fluorescence should
closely correlate with changes in proliferation, as this method is monitoring DNA content
and hence cell number.
NCI-1876 cells were also assayed and showed no significant changes in proliferation or
signaling in response to NPA as revealed by Cyquant assay (data not shown). This is an
appropriate negative control for experiments as these cells express D2R dopamine
receptors but are refractory to signaling by DA agonists (Senogles, unpublished
observations).
Several methods could have been employed in order to generate greater changes in
proliferation. The assay might have been optimized by determining the time of maximum
change in proliferation, by determining fluorescence at 12 hours, 18 hours, 24 hours and
36 hours. In addition, cell synchronization might augment the changes in proliferation.
Optimization of the effects likely would evoke similar changes to those seen in other DA
responsive cells and tissues such as anterior pituitary cells (Pawlikowski 1978) primary
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lactotroph cultures (Senogles 1994; Stepien 1978) and SCLC cells and tissues (Ishibashi
1994; Senogles 2007).
Previous results from this laboratory suggest that this effect is a D2R specific
phenomenon. NPA as a DA agonist has a higher specificity for D2R like receptors, but
does not differentiate well between D2R and D3 isoforms. SCLC cell lines have been
assayed using RT PCR using probes specific for DA receptor subtypes. In NCI-H69 cells
(Senogles 2007) and DMS 53 (Senogles unpublished) cell lines, both forms of D2R
receptors were present, but other D2R like receptors, such as D3 were not detectable.
D2R RECEPTOR STIMULATED REDUCTION OF pERK
IMMUNOREACTIVITY IN DMS 53 CELLS
Experimental Reasoning
Treatment of lactotroph cells with a D2R agonist has been reported result in a reduction
of TRH stimulated pERK (Banihashemi and Albert 2002). In an SCLC cell line, NCI
H69, our laboratory has demonstrated that treatment with NPA will result in a reduction
of pERK immunoreactivity and in ERK kinase activity (Senogles, unpublished
observations). These results have yet to be confirmed in the DMS 53 cell line. As a
result, we wanted to investigate changes in ERK phosphorylation in these cells before
and after treatment with NPA. Cells were treated with 1 µM NPA in 10 µM HCl or with
vehicle containing a final concentration of 10 µM HCl and incubated for four hours prior
to lysis.
Results of pERK Western Blot Analysis
As shown in Figure 3.2, treatment with NPA decreased the total amount of
phosphorylated ERK in DMS 53 cells. This result is in agreement with results previously
observed GH4ZR7 in NCI-H69 cells (Senogles unpublished observations). Stripping of
the blot followed by re-probing with an antibody to actin showed no change in actin
expression. The phosphorylation of ERK was changed over 4 hours, but the protein
expression probably did not change as actin protein levels were constant.
Discussion of pERK Western Blot Analysis
The results here demonstrate pERK immunoreactivity changed following the addition of
NPA and suggest that pERK levels decrease in response to treatment with D2R agonist.
Actin was used as a loading control for this blot, and the amount of actin did not change
over time. However, we remain uncertain that DA agonist addition was not decreasing
total ERK levels as well. Typically, pERK blots are reprobed for total ERK using a panERK antibody which would determine total ERK.
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Figure 3.2. pERK Immunoreactivity following NPA Treatment. DMS 53 cells were
treated with 1 µM NPA for four hours. Cells were harvested and lysates were subjected
to SDS-PAGE and Western Blot was performed using a polyclonal anti-pERK antibody.
The blot was visualized with enhanced chemiluminescence.
However, we should still investigate an exact timeline to determine the point of
maximum change in pERK. In NCI-H69 cells pERK levels decrease with time of NPA
treatment (Senogles unpublished observations). This result suggests either a reduction of
MEK activity or an increase in phosphatase activity. Our laboratory has demonstrated
that MEK kinase activity does not change in response to DA agonists (Senogles
unpublished observations). Thus, the reduction in phosphorylation is likely the result of
greater phosphatase activity. We chose to investigate the potential role of phosphatases in
this effect. Members of the DUSP family exhibit varied specificities of MAPKs and
ERK specifically. We chose to identify members of this family through real time PCR.
Real time PCR analysis would enable us to quickly identify which DUSP changed with
DA agonist addition.
SIGNIFICANT ELEVATION OF DUSP1, DUSP4 AND DUSP5 EXPRESSION
FOLLOWING NPA TREATMENT
Experimental Reasoning
Unpublished results from our laboratory suggested that ERK phosphorylation and kinase
activity was decreased in response to D2R agonist treatment (Senogles, unpublished
observations). We wanted to determine what was leading to these changes. The
laboratory had previously demonstrated that the reduction in ERK phosphorylation was
not due to decreased MEK activity which would result in lower ERK phosphorylation
(Senogles unpublished). In vitro kinase assays using a recombinant ERK as substrate,
demonstrated that treatment of cells with NPA did not result in a decrease of MEK
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activity (Senogles, unpublished observations). As ERK phosphorylation can be regulated
either by upstream kinases (MEK) or downstream phosphatases, we chose to investigate
the involvement phosphatases in this phenomenon. Our cells are growing in media
supplemented with fetal bovine serum. As a result, the cells are actively proliferating in
response to growth factors present in the sera. Our hypothesis is that NPA treatment turns
on a signaling cascade which results in the change of expression or activity of a
phosphatase which results in ERK becoming dephosphorylated and leading to a decrease
in proliferation. In our hypothesis, members of the DUSP family of proteins are
potentially important regulators of ERK phosphorylation and we have chosen to
investigate the effect of NPA on DUSP expression in DMS 53 cells.
As we showed in our hypothetical pathway in Figure 1.2, AA may play a role in the
antiproliferative effect by D2R agonists. As summarized previously, agonist treatment of
D2Rs transfected CHO cells resulted in release of AA (Piomelli 1991). In addition, there
is evidence from another laboratory which is relevant. In Vascular Smooth muscle cells,
AA stimulates increases in DUSP1 expression with subsequent changes in protein levels
(Metzler 1996). This increase in DUSP1 results in a concomitant reduction of
proliferation. It is our hypothsis that D2R stimulated signaling may result in AA release
which results in changes in DUSP expression.
Thus, we wanted to determine the expression changes of several DUSP genes following
D2R receptor stimulation with NPA in the SCLC cell line, DMS 53. Gene expression
data for eight different DUSPs were evaluated using real time PCR analysis. DMS 53
cells were treated with NPA for the following intervals:1 hr, 2 hrs or 6 hrs. Controls were
treated with vehicle: 10 µM HCl. See Materials and Methods for details of RNA
extraction, reverse transcription and discussion of real time PCR.
Result of NPA Treatment Addition to DMS 53 Cells
DUSP1
A comparison of vehicle and NPA treated DMS 53 cells revealed significant increases in
DUSP1 (MKP-1) at 1 hr, 2 hrs and 6 hrs (Figure 3.3). All of the real time PCR data were
standardized using cyclophilin as a control gene. We had shown that cyclophilin was the
least variable of all of the housekeeping genes. At 1 hr, 1 µM NPA treatment led to 0.18
fold increase (n=18, p<0.01) of DUSP1. At 2 hrs, DUSP1 expression was elevated 0.57
fold compared to vehicle (n=60, p<0.001), while at 6 hrs change in expression was at the
highest with a 0.63 fold increase (n=49, p<0.001) (Figure 3.3). These results
demonstrated a time dependent increase in DUSP1 expression following NPA treatment.
DUSP4
NPA treatment treatment brought about a marginal reduction in DUSP4 (0.16 fold) at 1
hr (n=13, p<0.05). However, at later time points and with larger sample sizes, increases
were seen. DUSP4 expression increased with NPA treatment 0.11 fold at 2 hrs (n=70,
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Figure 3.3. Real Time PCR Analysis of DUSP1 Expression in DMS 53 Cells
following Addition of NPA, a D2R Agonist. All samples were standardized using
cyclophilin D. The fold change is calculating taking the NPA treated samples divided by
the vehicle. A baseline of zero indicates no change compared to vehicle control.
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p<0.001) and was at a maximum of 0.17 fold increase at 6 hrs (Figure 3.4).
DUSP5
Significant increases in DUSP5 were seen at 2 hrs with a 0.26 fold increase over vehicle
(n=66, p<0.001) following D2R stimulation with NPA (Figure 3.5). DUSP5 levels
increased even more at 6 hrs, reaching a 0.46 fold increase (n=63, p<0.001). These results
demonstrate a significant time dependent increase in DUSP 5 expression after NPA
treatment.
DUSP2
DUSP2 (Figure 3.6) demonstrated small changes in expression. While changes were
evident, these small changes appeared to achieve significance due to repetition.
Other DUSP Family Members
Other DUSP family members were evaluated for changes in expression following NPA
treatment of DMS 53 cells. Shown (Figure 3.7) are the results for DUSP 3, 6, 7, 9 and 14
after treatment for 1, 2 or 6 hours with NPA. For the sake of comparison, the previously
shown results for DUSP 2 are displayed. The expression of DUSP 3, 6, 7 and 9 does not
rise over 0.2 fold compared to vehicle controls. While these measurements have
significance due to the large number of repetitions, the changes observed are not large.
DUSP 14 showed changes in expression with NPA treatment at 2 and 6 hours which were
over 0.3 compared to vehicle control.
Discussion of NPA Addition to DMS 53 Cells
Real time PCR revealed statistically relevant increases in DUSPs 1, 2, 4, 5, 6 and 14.
We believe some of the small variations observed (between 0.2 to -0.2) represent the
experimental variation caused by evaluation of real time PCR. At this level of change, it
is difficult to determine whether any actual change in mRNA is occurring. While
statistical significance was reached for DUSPs 2, 4, 6, 14 the minor levels of change are
close to those seen in cases of statistical variation. The reliability and biological
significance of the changes seen in these genes is questionable. In order to maximize the
reliability of this assay, the experiments were performed on multiple days.
Increases in DUSP1 and DUSP5 were evident as early as 2 hours and remained elevated
until 6 hours. These increases tripled the estimated experimental variation and the
changes in these two genes occurred consistently.
While statistically significant, the biological relevance of these minor changes in mRNA
are in question. Do these minimal changes represent actual changes in genes expression?
Are the changes large enough to result in subsequent changes in protein levels? The
increases in mRNA seen were relatively minor and increased transcription may be the
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Figure 3.4. Real Time PCR Analysis of DUSP4 in DMS 53 Cells following
Treatment with NPA. All samples were standardized using cyclophilin D. The fold
change is calculated by taking the NPA treated samples divided by the. A baseline of
zero indicates no change compared to vehicle control.
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Figure 3.5. Real Time PCR Analysis of DUSP5 in DMS 53 Cells following
Treatment with NPA. All samples were standardized using cyclophilin D. The fold
change is calculated by taking the NPA treated samples divided by the vehicle. A
baseline of zero indicates no change compared to vehicle control.
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Figure 3.6. Real Time PCR Analysis of DUSP2 in DMS 53 Cells following
Treatment with NPA. All samples were standardized using cyclophilin D. The fold
change is calculated by taking the NPA treated samples divided by the vehicle. A
baseline of zero indicates no change compared to vehicle control.
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Figure 3.7. Real Time PCR Analysis of DUSP Family Members in DMS 53 Cells
following NPA Treatment. All samples were standardized using cyclophilin D. The
fold change is calculated by taking the NPA treated samples divided by the vehicle. A
baseline of zero indicates no change compared to vehicle control. The data for DUSP1
and DUSP5 (Figure 3.3 and 3.5 are shown again for a comparison).
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source. Instead, decreased degradation of mRNA may lead to these changes. In order to
determine which effect is occurring, NPA induction while halting transcription could be
analyzed. If halting transcription inhibits the NPA induction of the DUSP genes, the
induction is likely occurring through increased transcription. Three of the genes increased
in this assay, DUSP1, DUSP4 and DUSP5, are all nuclear-inducible genes. While the
changes are modest, the fact that primarily putative inducible DUSPs are involved
suggests that actual increased expression of these genes is more likely. If degradation
was occurring, it would possibly affect both classes of genes equally.
In order to determine if subsequently protein levels were being increased, we wanted to
assess these changes through Western Blot. Real time PCR results revealed the greatest
increases of mRNA in DUSP1 and DUSP5, as result we decided to investigate these
genes. Preliminary results from DUSP4 (MKP-2) western blots showed DA dependent
increases (Senogles unpublished). This information, together with real time PCR results
for DUSP4, led us to further investigate this gene as well. NPA treatments for these all
three of these genes, which were used as controls in later real time PCR experiments,
consistently resulted in increases in mRNA.
NPA INCREASES IN DUSP5 AS REVEALED BY WESTERN BLOT
Experimental Reasoning
As we had observed increased mRNA expression for DUSP1, DUSP4 and DUSP5 and
we wanted to determine if protein levels were also changing. Previously, western blots
were performed, which had demonstrated increases in MKP-2 (DUSP4), but none for
MKP-1 (DUSP1) (Senogles unpublished). Due to technical difficulties with
commercially available antibodies and time constraints, we were unable to evaluate all of
these proteins for this thesis by Western Blot analysis. Due to the consistent changes in
DUSP5 expression after NPA treatment we chose to investigate changes in DUSP5
protein expression. DUSP5 also has a high specificity of ERK and overexpression has
been known to reduce ERK phosphorylation (Owens and Keyse 2007). DUSP5 anchors
ERK in the nucleus, maintaining ERK in a dephosphorylated state and leads to a
reduction in proliferation (Keyse 2005).
Result of DUSP5 Western Blot Analysis
NPA stimulation of DMS 53 with 1 µM NPA for 2hours and 6 hours brought upon
increases in DUSP5 protein over 10 µM HCl as a vehicle control, as revealed by western
blot analysis with a DUSP5 specific antibody (Figure 3.8). These changes were
reproducible and cell types specific. Marked increases in DUSP5 were observed
compared to 10 µM HCl in DMS 53 cells, but not SCLC NCI-1876 cells (Figure 3.9).
NCI-1876 cells are unresponsive to the effect of DA and are a negative control (Senogles
unpublished observations).
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Figure 3.8. Western Blot of DUSP5 Protein Expression Time Course after
Treatment with NPA. DMS 53 cells were treated in the presence and absence of 1 µM
NPA for the times indicated. Lysates were prepared from these cells and subjected to
SDS-PAGE and Western blotting. The blots were visualized with Anti-DUSP 5 antibody
and chemiluminescence. The blot was stripped and reprobed with anti-actin antibody.

Figure 3.9. Western Blotting of NPA Induction of DUSP5 Using NCI-1876 Cells as a
Negative Control. DMS 53 cells and NCI-1876 cells were treated with 1 µM NPA for 2
hours. Lysates were prepared from these cells and subjected to SDS-PAGE and Western
blotting. The blots were visualized with Anti-DUSP 5 antibody and chemiluminescence.
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Discussion of DUSP5 Western Blot Analysis
The expression of DUSP5 proteins increased the largest at two hours (Figure 3.8) with
more modest increases observed at 1 hours and 4 hours. At 2 hours the intensity density
of the Actin control also remains consistent. As expected, no increase was seen in NCI1876 cells, which do not respond to DA by reducing proliferation or signaling to adenylyl
cyclase or PLD. Protein concentrations levels were standardized prior to electrophoresis
and western blot analysis to minimize variation.
Other western blots of Actin protein suggest that NPA does not stimulate change in actin.
However, a control where the DUSP5 blot in Figure 3.9 was stripped and reprobed for
Actin or other housekeeping protein is necessary for confirmation.
We were still left with questions about the mechanisms leading to the increase in DUSP5
protein and how these changes affect ERK phosphorylation and proliferation. NPA
induction of DUSP5 protein was greatest at 2 hours. Real time PCR revealed the greatest
increases between 2 hours and 4 hours. The quality of the time course for the western blot
does not give enough information about whether the protein levels remain elevated
between 2 hours and 6 hours. This timeframe is important because the pERK changes
were seen at 4 hours. In NCI-H69 lines our laboratory reported that pERK was reduced
prior at times longer than hour suggesting this effect occurs very quickly.
Further analysis of both proteins should be carried out by stripping and reprobing the
same western blot to further correlate the times. DUSP5 may lead to an overall reduction
in ERK phosphorylation levels. In addition, DUSP5 might reduce ERK phosphorylation
in the nucleus, which might not be detectable by analyzing total pERK levels. It has been
reported that DUSP5 anchors ERK in the nucleus and isolates ERK cytosolic kinases and
targets (Keyse 2005). Localization is an important factor in how ERK signals.
Determining how pERK localization correlates with that of DUSP5 is an important next
step in understanding the pathway for D2R mediated proliferation. Also, an assay to
determine if D2R signaling generates increases in phophatase activity would help to
determine that DUSP activity is leading to reductions in pERK.
While only correlations, these results suggest that D2R activation results in increases in
DUSP5 mRNA and protein, and putatively leads to reduced ERK phosphorylation. Much
information about the D2R signaling pathway has been determined in other cell lines.
We sought to determine the intermediates leading to the increased DUSP5 expression. In
NCI-H69 cells, the D2R mediated antiproliferative effect was reported to be mediated by
PLD (Senogles 2007). We wanted to determine if PLD was involved in induction of
DUSP5.
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ETHANOL INHIBITION OF NPA MEDIATED INDUCTION OF DUSP5 AND
DUSP4, BUT NOT DUSP1
Exerimental Reasoning
Treatment of DMS 53 cells with NPA resulted in increases in DUSP1, DUSP4 and
DUSP5 mRNA expression were observed through real time PCR. Our overarching
hypothesis is shown in Figure 1.2. Activation of the D2R receptor stimulates PLD
activity. The PLD generated PA, possibly through the action of PLA2 results in the
release of AA. The AA or a metabolite of AA is responsible for the changes in mRNA for
the DUSPs. This change in expression of DUSPs results in the dephosphorylation of
pERK and a resultant reduction in proliferation.
We wanted to test if known inhibitors of the antiproliferative effect would also inhibit the
increases in the mRNA of the DUSP family of genes. To this end, we selected two
inhibitors of the D2R mediated signaling pathway (Figure 1.2). Phospholipase D has been
demonstrated to mediate the antiproliferative effect in primary lactotrophs as well as in
SCLC cell line, NCI-H69 (Senogles 2007). In order to determine if PLD was also
involved in DUSP induction, ethanol was added to inhibit the generation of PA. As
mentioned previously, PLD can use a primary alcohol as substrate with the generation of
phosphatidylethanol instead of PA. The addition, of ethanol to DMS 53 cells, results in
the inhibition of PA dependent downstream signaling.
DMS53 cells were treated with 1 µM NPA, 1 µM NPA plus 0.5% ethanol or ethanol
alone. NPA was added for 6 hours, while ethanol addition was delayed and remained on
cells for the final 2 hours.
Result of Ethanol Addition Experiment
DUSP5
Ethanol treatment of DMS 53 cells reduced the previously observed NPA induction of
DUSP5 mRNA (Figure 3.10). The 0.28 fold induction (n=45, p<0.001) of DUSP5 by
NPA was reduced 29% (n=51, p<0.05) to 0.20 fold above vehicle in conjunction with
0.5% Ethanol addition to NPA. Ethanol alone did not affect significantly affect DUSP5
expression compared to vehicle control (n=27, p=0.65).
DUSP4
NPA induced, DUSP4 (MKP-2) expression was minimal at 0.10 fold above vehicle
(Figure 3.11), but statistically significant (n=23, p<0.05). This induction was completely
abolished when Ethanol was added in conjunction with NPA (n=23, p<0.001).
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Figure 3.10. Effect of Ethanol on DUSP5 Expression as Revealed by Real Time
PCR. DMS 53 cells were treated for 6 hour with 1 µM NPA, 1 µM NPA + 0.5%
ethanol for 2hours or ethanol alone. All samples were standardized using
cyclophilin D. The fold change is calculated by taking the NPA treated samples
divided by the vehicle. A baseline of zero indicates no change compared to vehicle
control.
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Figure 3.11. Effect of Ethanol on DUSP4 Expression as Revealed by Real Time
PCR. DMS 53 cells were treated for 6 hours with 1 µM NPA, 1 µM NPA + 0.5%
ethanol for 2 hours or ethanol alone All samples were standardized using cyclophilin D.
The fold change is calculated by taking the NPA treated samples divided by the vehicle.
A baseline of zero indicates no change compared to vehicle control.
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DUSP1
In contrast, the expression of DUSP1 mRNA (MKP-1) was increased by Ethanol as
compared to vehicle control (Figure 3.12). Addition of Ethanol alone resulted in 0.37 fold
increases of DUSP1 (n=25, p<0.001). As a result, the NPA induced DUSP1 expression
was actually increased from 0.5 fold above vehicle (n=32, p<0.001) to 0.67 fold (n=46,
p<0.001) compared to vehicle. This additional 25% induction of DUSP1 by Ethanol and
NPA, reached marginal statistical significance of p<0.05.
Other DUSP Family Members
Addition of Ethanol alone had little effect on the expression of mRNA of other DUSPs
tested (data not shown). The expression of DUSP3 mRNA was marginally reduced by
ethanol alone (n=25, p<0.05), with a 0.19 decrease compared to vehicle control. In
addition Ethanol statistically increased DUSP9 mRNA expression by 0.15 fold. Neither
DUSP2 (n=25, p=0.997), DUSP6 (n=27, p=0.84), DUSP7 (n=26, p=0.84) or DUSP14
(n=7, p=0.97) mRNA expression were changed significantly by addition of Ethanol.
Discussion of Ethanol Addition Experiment
Ethanol inhibited the NPA induction of DUSP4 and DUSP5. Ethanol alone did not
significantly effect the expression of either of these genes. The Ethanol and NPA
combination did not result in reduced DUSP1 compared to levels seen in NPA treated
cells. However, Ethanol alone did increase DUSP1 mRNA relative to vehicle control.
For this reason we suspect that Ethanol related cellular stress activates another pathway.
DUSP1 has little preference for JNK, p38 and ERK as substrates (Owens and Keyse
2007). As a result, DUSP1 is involved in a large number of processes and has been
shown to be rapidly induced by inflammatory stimuli (Wang 2007). As a result it is
difficult to test how the inhibition of PA production through ethanol may affect the NPA
induction of this gene. In other cell lines, ethanol treatment inhibits the antiproliferative
effects of DA (Senogles 2007). This suggests that DUSP1 is not involved in this process,
a hypothesis that is supported by the inability of NPA to induce MKP-1 (DUSP-1)
through western blot.
This collection of data suggests that DUSP 4 and 5 may be the phosphatases involved in
the antiproliferative effect of D2R agonists. The expression of mRNA for both DUSP 4
and 5 was sensitive to the presence of ethanol, which suggested that the mRNA for these
proteins may be regulated by PLD.
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Figure 3.12. Effect of Ethanol on DUSP1 Expression as Revealed by Real Time
PCR. All samples were standardized using cyclophilin D. The fold change is calculated
by taking the NPA treated samples divided by the vehicle. A baseline of zero indicates no
change compared to vehicle control.
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INCREASED DUSP1, DUSP4 AND DUSP5 EXPRESSION FOLLOWING AA
TREATMENT
Experimental Reasoning
AA involvement in the induction of DUSP1 (MKP-1), as observed by Metzler et al.
1996, occurred in Vascular Smooth muscle cells. D2R potentiated AA release has been
demonstrated in CHO (Piomelli 1991), lactotroph and SCLC cell lines (Senogles,
unpublished observations). In DMS 53 cells, we have observed D2R potentiated
increases in several of the DUSPs. We wanted to determine if direct application of AA
would generate similar changes in expression of these genes in DMS 53 cells as those
observed with NPA treatment. AA, from Porcine Liver, Sodium Salt (Calbiochem) was
stored in -20 C, dissolved in distilled-deionized water before adding to cells. AA was
added to cells for 5 hours prior to lysis.
Result of AA Treatment of DMS 53 Cells
Significant concentration-dependant increases were seen in DUSP1 (MKP-1), DUSP4
(MKP-2) and DUSP5 mRNA’s following the addition of AA. Note that these
experiments are performed in the absence of NPA as we are evaluating the effects of AA
alone.
DUSP1
Treatment of DMS 53 cells with AA resulted in an increase of expression for the mRNA
for DUSP1 (MKP-1) compared to vehicle control levels (Figure 3.13). The increases in
DUSP1 mRNA expression demonstrated concentration dependence up to 50 µM.
Significant increases in mRNA for DUSP1 were observed with addition of 10 µM (0.22
fold change, n=21, p<0.001), 50 µM (0.68 fold change, n=92, p<0.001) and 200 µM
(0.53 fold change, n=15, p<0.001). At 1 µM concentration of AA, a minor inhibition of
0.06 fold in mRNA expression was observed (n=30, p<0.001).
DUSP4
The addition of AA to DMS 53 cells resulted in significant increase of the mRNA for
DUSP4 at 50 µM and 200 µM (Figure 3.14). The changes in DUSP4 were the strongest
with 50 µM addition (0.33 fold increase, n=73, p<0.001) even more than those seen at
200 µM (0.10 fold increase, n=21, p<0.001).
DUSP5
DUSP5 showed a dose dependence on AA concentration. The changes in mRNA
observed gradually increased, with 0.16 fold increases seen at 10 µM AA addition. The
changes were larger (0.33 fold, n=74, p<0.001) at 50 µM and reached the
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Figure 3.13. Effect of AA on DUSP1 Expression as Revealed by Real Time PCR
Analysis. All samples were standardized using cyclophilin D. The fold change is
calculated by taking the NPA treated samples divided by the vehicle. A baseline of zero
indicates no change compared to vehicle control.
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Figure 3.14. Effect of AA on DUSP4 Expression as Revealed by Real Time PCR
Analysis. All samples were standardized using cyclophilin D. The fold change is
calculated by taking the NPA treated samples divided by the vehicle. A baseline of zero
indicates no change compared to vehicle control.
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maximum of 0.58 fold (n=15) at 200 µM (Figure 3.15).
Of the remaining DUSP genes, minimal changes in expression of mRNA were seen
(Figure 3.16) and those changes were only seen at 200 µM for DUSP 3 (0.08 fold,
p<0.01, n=15) at 50 µM for DUSP 9 (0.10, n=58, p<0.05) and DUSP 14 (0.08 fold, n=51,
p<0.05). No changes in expression of mRNA for DUSP7 expression were evident.
Discussion of AA Treatment of DMS 53 Cells
The addition of AA to DMS 53 cells resulted in significant changes in DUSP1 in as little
as 10 µM and increased until 50 µM. Induction of DUSP1 at 200 µM fell slightly
compared to those at 50 µM. This may indicate that some other factor is being changed at
high concentrations. More likely however is that the difference between these two is an
experimental difference. At 200 µM the number of trials was reduced, increasing the
likelihood that greater variation may be seen. Increases in AA induced DUSP5 increased
with concentration, reaching a maximum at 200 µM. These levels were markedly above
the levels of increased mRNA expression seen by random experimental variation. The
results here suggest that AA does induce DUSP5. DUSP4 reached a maximum at 50 µM.
At this concentration, the levels were above 0.30 fold change, approximately double
those seen in genes with no change. At this concentration enough trials were performed
to reduce unwanted statistical variation. Taken together these data suggest that AA
induces mRNA expression of DUSP1, DUSP4 and DUSP5.
Addition AA resulted in ablation of NPA induced DUSP mRNA. We were unsure exactly
how PA may be leading to increased DUSP expression. Our overall hypothesis was that
AA was being produced downstream of PA. The changes in expression induced by AA
were similar in magnitude to the changes observed in response to NPA. In both
experiments we witnessed the greatest changes in DUSP1 and DUSP5 with minor
increases in DUSP4. This correlation suggests that AA may in fact be produced in
response to NPA and this production may lead to the induction of DUSP1, DUSP4 and
DUSP5. However, we have yet to establish that AA production as a result of DA
signaling actually led to the induction of the mRNA of these three genes. We sought to
inhibit the actions of AA following NPA addition and then evaluated the induction of
these genes.
REDUCTION OF DUSP1, DUSP4 AND DUSP5 INDUCTION BY NPA
FOLLOWING ADDITION OF AA INHIBITORS
Experimental Reasoning
As shown in the previous section, AA alone would bring about changes in the mRNA
expression for a number of DUSPs. Our hypothesis is that if NPA induced expression of
DUSPs is AA dependent, an inhibitor of AA should block the changes in mRNA
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Figure 3.15. Effect of AA on DUSP5 Expression as Revealed by Real Time PCR
Analysis. All samples were standardized using cyclophilin D. The fold change is
calculated by taking the NPA treated samples divided by the vehicle. A baseline of zero
indicates no change compared to vehicle control.
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Figure 3.16. Effect of AA on DUSP Expression as Revealed by Real Time PCR
Analysis. All samples were standardized using cyclophilin D. The fold change is
calculated by taking the NPA treated samples divided by the vehicle. A baseline of zero
indicates no change compared to vehicle control.
observed with AA. For this reason, we chose to investigate the effects of ETYA on
expression of DUSPs by real time PCR.
5,8,11,14-eicosatetraynoic acid (ETYA) is a cell permeable and nonhydrolyzable analog
of AA (5,8,11,14-eicosatetraenoic acid), which competitively inhibits AA (Ondrey 1989;
Taylor 1985). ETYA has been shown to inhibit phospholipase A2 (PLA2) and
cytochrome P-450. In addition, it has also been shown to inhibit cyclooxygenase, 5lipoxygenase, 12-lipoxygenase and 15-lipoxygenase (Ekokoski 1994; Honda 1999;
Ondrey 1989).
NPA was added to all conditions at a concentration of 1 µM. ETYA was dissolved in
DMSO and added to culture media at a final concentration of 10 µM ETYA and 0.01%
DMSO. The conditions for treatment were NPA or NPA with ETYA/DMSO or DMSO
alone. Each well of a six well cluster dish corresponded to one condition: NPA alone,
NPA plus ETYA/DMSO or NPA plus DMSO alone and cells were allowed to incubate in
normal culture conditions for 4 hours. At the end of the test period, media was aspirated,
cells were washed and RNA extracted as described in methods.
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Result of ETYA Addition to DMS 53 Cells
DUSP1
As confirmation of previous results, NPA increased DUSP1 expression 0.72 fold above
vehicle control (n=42, p<0.001) as shown in Figure 3.17. The addition of 10 µM ETYA
in 0.01% DMSO reduced the mRNA for DUSP1 by 46% compared to NPA alone, and
0.39 fold compared to the DMSO vehicle (n=60, p<0.001). The changes in DUSP
expression were not a result of DMSO present in the media as DMSO alone did not
significantly change NPA induced DUSP1 expression resulting in 0.65 fold increase over
vehicle (n=30, p=0.38).
DUSP5
Addition of NPA alone resulted in a 0.45 fold increase in DUSP5 mRNA expression over
vehicle control. This increase in expression by NPA was ablated by 56.5%
with the inclusion of ETYA compared to vehicle (n=48, p<0.001). The addition of
DMSO (0.341 fold, n=36, p=0.16) did not significantly inhibit DUSP5 mRNA induction
by NPA (Figure 3.18).

Figure 3.17. Effect of 10 µM ETYA Added to 1 µM NPA Treatment on DUSP1 as
Revealed by Real Time PCR. Fold change is calculated relative to vehicle control.
Significance levels in the upper portion of the graph represent the comparison of NPA
alone to the other treatment conditions.
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Figure 3.18. Effect of 10 µM ETYA Added to 1 µM NPA Treatment on DUSP5 as
Revealed by Real Time PCR. Fold change is calculated relative to vehicle control.
Significance levels in the upper portion of the graph represent the comparison of NPA
alone to the other treatment conditions.
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DUSP4
While the addition of NPA increased the expression of mRNA for DUSP4 (MKP-2) 0.23
fold compared to control (n=36, p<0.001), these changes were similar to those seen
overall (Figure 3.19). The induction of DUSP 4 mRNA by NPA was completely
abolished by ETYA (n=54, p<0.001) and registered a reduction of mRNA expression by
0.21 fold compared to vehicle (p<0.001).
Discussion of ETYA Addition to DMS 53 Cells
The addition of ETYA resulted in complete inhibition of NPA mediated increases in
DUSP4 and partial inhibition of increases in DUSP1 and DUSP5. DMSO as a vehicle did
not have any effect on the NPA induction of these genes. These results indicate that AA
is involved in the NPA induction of these genes. Following the induction of these DUSPs
with external application of AA, we expected DUSP4 and DUSP5 to be inhibited by
ETYA. The induction of both of these genes appeared to be dependent on PA as indicated
by the inhibition with ethanol. Our expectation was that PA produced would be
metabolized to AA.
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Figure 3.19. Effect of 10 µM ETYA Added to 1 µM NPA Treatment on DUSP4
Expression as Revealed by Real Time PCR. Fold change is calculated relative to
vehicle control. Significance levels in the upper portion of the graph represent the
comparison of NPA alone to the other treatment conditions.
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CHAPTER 4. SUMMARY/CONCLUSION
Our overarching hypothesis was that the D2R dopamine receptor mediated signaling
impacted the expression of DUSP family of proteins. We hypothesized that the D2R
receptor, through stimulation of PLD and generation of PA, would impact DUSP
expression. The proposed pathway suggests that PA may be metabolized through the
action of cPLA2 to generate AA. AA generated in this method might directly or
indirectly lead to increased DUSP mRNA, followed by greater protein levels and
phosphatase activity generated toward ERK.
Our first step to evaluate this hypothesis was to confirm D2R mediated antiproliferation
in DMS53 cells.We observed modest reductions in proliferation through the cyquant NF
proliferation assay, which is based on DNA content of cells. We concluded that in this
SCLC cell line that NPA would result in a reduction in proliferation. This effect has been
observed by our laboratory in other SCLC cell lines as well as GH4C1 and HEK cells
transfected with the cDNA of the D2R. Next we sought to determine if expression of any
DUSP genes were increasing following D2R stimulation. We chose to use RT-PCR for
this set of experiments. The primary reason for this choice was that we could we could
evaluate a number of DUSP genes simultaneously. Primers for DUSP1, 2, 4, 5, 6, 7 and
14 were validated and expression levels were determined through real time PCR analysis.
We evaluated gene expression for each of these genes in the presence and absence of
NPA and found a number of changes. Addition of NPA resulted in significant increases
in the expression of DUSP1 (MKP-1), DUSP4 (MKP-2) and DUSP5 mRNA. We
observed increases in all three genes at the two and six hour time points. Insignificant
levels of the remaining DUSPs demonstrated the experimental variation involved in the
real time PCR and indicated the sensitivity of the assay. Changes following addition of
NPA of the mRNA for DUSP4 and DUSP14 were in the range that we believed to be due
to experimental variability as determined by evaluating how genes with no statiscal
significance varied positively and negatively inside this range. As changes in expression
for these genes were inside this range, we had reason to expect type one statistical errors
even though statistical significance was reached. NPA consistently induced changes in
DUSP4 in each experiment where NPA induction was used as a positive control. In
addition, we had previously seen NPA induced changes in MKP-2 (DUSP4) in other
SCLC cell lines, leading us to believe that the modest NPA induced changes in DUSP4
mRNA may contribute to changes in protein levels. While the DUSP4 levels were
modest, DUSP1 and DUSP5 were induced at the highest levels of significance and
approximately three times the experimental variation.
Next, we wanted to determine the signaling pathway leading to increased DUSP1,
DUSP4 and DUSP5 expression. We tested whether NPA induced expression of these
genes could be inhibited by inhibiting PA production, using ethanol. Ethanol inhibited
NPA induction of DUSP4 and DUSP5, but not DUSP1. Ethanol reduced NPA mediated
increase in DUSP5 nearly thirty percent and completely abolished the NPA mediated
increase in DUSP4. As a surprise, when added to NPA treated cells, 0.5% Ethanol,
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actually increased DUSP1 expression. The induction of DUSP1 by ethanol was also
observed in the absence of NPA.
We wanted to determine how PA generated through PLD might lead to induction of these
genes. We hypothesized that DUSP induction might occur through the metabolism of PA
and eventual production of AA. Real time PCR revealed dose dependent, AA induced
increases in mRNA for DUSP1, DUSP4 and DUSP5 which mimicked the changes
induced by NPA. At similar levels, DUSP1, DUSP4 and DUSP5 were increased by
treatment with AA. These results confirmed that mRNA for these genes was increased
through external application of AA. Inhibitors of the action of AA, such as ETYA were
used to determine if they could block the effects of NPA. The NPA mediated increases
in all three of these genes were inhibited by treatment with ETYA. NPA induced
significant increases in DUSP1, DUSP4 and DUSP5. ETYA reduced or eliminated the
increases due to NPA addition of all three of these DUSP genes. DMSO as a vehicle did
not significantly decrease any of the three genes.
Taken together, this information suggests the following conclusion. Expression of
DUSP1, DUSP5 and DUSP4 expression levels are mediated by the D2R, activated by
NPA. The role of PLD has been shown as ethanol will ablate the changes in mRNA
observed with NPA treatment. In addition, treatment of DMS 53 cells with exogenous
AA mimics the effects observed with D2R agonist. These data are consistent with a
model in which D2R agonists stimulate PLD, resulting in the release of PA which is
metabolized to AA. In turn, AA either directly or through a metabolite, brings about the
increases in DUSP mRNA.
DUSP5 is the strongest candidate as the phosphatase responsible for the
dephosphorylation of ERK in the D2R mediated antiproliferative effect. Western Blot for
DUSP5 show subsequent changes in protein levels following NPA stimulation. Of the
nuclear inducible DUSPs, DUSP5 is also the most specific toward ERK (Owens and
Keyse 2007). Increased DUSP5 has been shown to bind ERK, inactivate it through
dephosphorylation and anchor it in the nucleus, thus preventing ERK from being
phosphorylated again (Keyse 2005). However, it should not be ruled out that these
DUSP genes are working in concert to reduce ERK phosphorylation as each of these
genes code for proteins which exhibit some phosphatase activity toward ERK (Owens
and Keyse 2007).
We hypothesize that these changes occur through the following pathway (Figure 4.1).
Treatment of DMS 53 cells with NPA results in the stimulation of PLD and the
production of PA. Ethanol inhibition of NPA stimulated expression of DUSP5 and
DUSP4 suggests the induction of these genes is dependant on PA released from PLD
activity. Metabolism of PA through unverified mechanisms generates AA. AA
generated from PA induces RNA expression of DUSP1 (MKP-1), DUSP4 and DUSP5
through unknown molecular mechanisms. The increased DUSP5 mRNA results in
increased protein which binds and dephosphorylates ERK.
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Figure 4.1. Proposed Mechanism for D2R Mediated Antiproliferation. D2R binding
indirectly activates PLD, which catalyzes the conversion of PC to PA. PA is metabolized
through unverified pathways leading to AA release. AA leads to increased DUSP5
mRNA and protein. DUSP5 binds phosphorylated ERK and dephosphorylates ERK.
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The information generated from these experiments answers some questions while others
are unanswered. AA dependent DA induction of DUSP4 and DUSP5 correlates with
changes in proliferation. Logically, DUSP induction would lead to reduction of pERK
and subsequently reduce proliferation. Several experiments remain to ensure that all of
the events in this thesis are directly connected. However, this information lends support
to the hypothesis that PLD is activated leading to AA release and subsequent changes in
DUSP5 and DUSP4 through unknown mechanisms.
Further investigation is required to determine whether DUSP expression directly
influences changes in ERK phosphorylation and activity and subsequent changes in
proliferation. We observed D2R mediated changes in ERK phosphorylation and also
increased DUSP5 immunoreactivity. It has been reported that DUSP5 can anchor in the
nucleus and reduce phosphorylation of ERK (Keyse 2005). Ultimately, we would like to
evaluate the cellular consequences of inhibiting DUSP5 specifically. However, DUSP5
specific inhibitors are not yet designed. Employing other technologies such as siRNA to
knockout DUSP5 and determining the effect on NPA reduction in proliferation and ERK
phosphorylation would allow us to determine if DUSP5 is sufficient to inhibit these
effects. This knockout also would answer questions or whether DUSP5 resides upstream
of ERK in the antiproliferative pathway.
Another question still left unanswered is the mechanism through which AA is generated
in this pathway. In our hypothesis there are two possible methods whereby PA might be
metabolized to AA (Figure 1.2). AA release is primarily a result of cytosolic
Phospholipase A2 (Lin 1992). If D2R receptor mediated DUSP expression is PLA2
dependent, this expression should be inhibited by PLA2 inhibitors.
In addition, questions remain about the discrepancies between the DUSP1 and the
DUSP4/DUSP5 induction by NPA. Ethanol may be inducing DUSP1 through a separate
mechanism. DUSP1 is largely involved in JNK expression. Ethanol may induce cellular
stress which is sufficient to induce JNK and DUSP1 expression is induced by JNK as a
feedback mechanism. DUSP1 induced through this pathway. Alternatively, PLD activity
may lead to localized concentrations of AA which generate changes in DUSP4 and
DUSP5, but do not effect on DUSP1 induction.
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